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Abstract
Background: Atrial fibrillation (AF) and hypertension are independently associated 
with impaired autonomic function determined using heart rate variability (HRV). 
As these conditions frequently co-exist, we sought to determine whether AF would 
worsen HRV in hypertensive patients.
Design: We studied HRV in AF (and hypertension) (n = 61) and hypertension con-
trol group (n = 33). The AF (and hypertension) group was subdivided into permanent 
AF (n = 30) and paroxysmal AF (n = 31) and re-studied. Time-domain, frequency-
domain and nonlinear measures of HRV were determined. Permanent AF group 
(n = 30) was followed up after 8 weeks following optimisation of their heart rate and 
blood pressure (BP).
Results: Time-domain and nonlinear indices of HRV were higher in AF (and hyper-
tension) group compared to hypertensive controls (P ≤ .01). Time-domain and non-
linear indices of HRV were higher in permanent AF group compared to paroxysmal 
AF (P ≤ .001). Permanent AF was an independent predictor of HRV on multivari-
able analysis (P = .006). Optimisation of heart rate and BP had no significant impact 
on HRV in permanent AF.
Conclusions: AF, independent of hypertension, is characterised with marked HRV 
and is possibly related to vagal tone. HRV is higher in permanent AF compared to 
paroxysmal AF suggesting evident autonomic influence in the pathophysiology of 
permanent AF. Modulation of autonomic influence on cardiovascular system should 
be explored in future studies.
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2 of 13 |   KHAN et Al.
1 |  INTRODUCTION
Atrial fibrillation (AF) is widely recognised as a significant 
cardiovascular condition associated with poor outcomes.1 
There is increasing evidence that abnormalities of the cardiac 
autonomic nervous system (ANS) are involved in the patho-
genesis of AF.2 The cardiac ANS has a significant role in the 
atrial environment, predisposing to the substrate, perpetua-
tors and triggers for AF.3 This includes direct electrophysio-
logical effects leading to alterations in atrial structure.3
In majority of patients with AF, reflex excitation of car-
diac myocytes due to AF itself together with involvement of 
concomitant risk factors such as hypertension, obesity and 
obstructive sleep apnoea influence cardiac ANS activity.3 As 
such, the cardiac ANS plays a central pathophysiological role 
in the initiation and progression of AF. Additionally, cardiac 
ANS activation might also determine the presence and se-
verity of AF-related episodes, such as dizziness, presyncope 
or syncope secondary to impaired baroreflex or carotid sinus 
sensitivity.4,5
Studies have reported that both sympathetic and para-
sympathetic branches of the cardiac ANS are involved in the 
pathophysiology of AF.6-8 Exploring cardiac ANS is pos-
sible through heart rate variability (HRV) evaluation. HRV 
has been studied extensively in patients with normal sinus 
rhythm and shown to have important prognostic implications 
for various cardiovascular disorders including hyperten-
sion.9-12 However, there have been limited reports examining 
HRV in AF.13-15
Barauskiene et al have shown that HRV is significantly 
lower in AF patients compared to controls.16 Conversely, 
Freedman and colleagues found HRV to be greater in lone 
AF than other cardiac disorders.17 Even then these studies ex-
amined HRV in AF patients while they were in sinus rhythm 
at the time of the study. However, using selective pharma-
cological blockade of cardiac sympathetic and parasympa-
thetic activity, van den Berg and colleagues determined that 
HRV is related to vagal tone in AF patients when not in sinus 
rhythm.13 Given these findings, and the high propensity of 
AF and hypertension to co-exist, we hypothesised that HRV 
will be worsened in patients with AF and hypertension, com-
pared to hypertension alone, and that optimisation of AF and 
BP therapy would improve HRV.
2 |  METHODS
2.1 | Participants
Eligible participants underwent screening against inclusion 
and exclusion criteria before being invited to take part in the 
study (see Supplementary Material). Participants were provided 
with detailed information sheets, and written informed consent 
was obtained from all participants, in accordance with the 
Declaration of Helsinki (2013). The study was approved by the 
Health Research Authority (HRA) and National Research and 
Ethics Service (NREC) Committee London—Camden & Kings 
Cross (18/LO/1064). Anonymised data and materials have been 
made publicly available at the Harvard Dataverse and can be ac-
cessed at https://doi.org/10.7910/DVN/ST2UUL. Reporting of 
the study conforms to broad EQUATOR guidelines.18
A total of 94 participants were recruited from the AF and 
hypertension services at Sandwell and West Birmingham 
Hospitals NHS Trust between October 2018 and March 
2019. No participants were excluded from the study after ini-
tial screening. The patients recruited were representative of 
the typical patients seen in outpatient clinics. We recruited 
2 groups of patients: those with AF (and hypertension) 
(n = 61) and hypertensive controls (n = 33). Patients with AF 
were stable on rate control and antithrombotic medication. 
The AF (and hypertension) group was further subdivided into 
permanent AF (n = 30) and paroxysmal AF (PAF) (n = 31). 
Permanent AF was defined as an episode of AF in which ef-
forts to restore normal sinus rhythm had either failed or been 
abandoned. PAF was defined as an episode of AF that termi-
nated spontaneously or with intervention in less than seven 
days. The hypertension control group included patients with 
hypertension (defined as previous diagnosis of hypertension 
or clinic BP of >140/90 mmHg) but not AF. These patients 
had additional cardiovascular risk factors similar to the other 
two groups and acted as the control group.
Initially, a cross-sectional age/gender-matched compar-
ison of the two main groups (AF (and hypertension) versus 
hypertension control) was carried out. This was followed by 
a comparison of the two subgroups of AF (and hypertension) 
group, that is PAF and permanent AF. Lastly, the patients with 
permanent AF (and hypertension) (n = 30) were studied longi-
tudinally with a single follow-up interval at 8 weeks duration 
following optimisation of their heart rate and BP medication. 
The medication optimisation was carried out by a single cli-
nician with experience in managing these conditions and in-
volved either increasing the dosage of existing cardiovascular 
medication or addition of new medication (for which the pre-
scription was provided) according to participants’ needs, al-
lergy status, known contraindications and clinical indication. 
These patients underwent the same measurements as at their 
first visit.
2.2 | Experimental protocol
Participants were expected to fast from food, water, caffeine 
and withhold their cardiovascular medications except anti-
coagulation for at least 12 hours prior to their appointment. 
At the study appointment, anthropometric measurements 
were taken to determine BMI (weight (kg)/height (m)2). An 
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ECG was performed on all participants to determine baseline 
heart rhythm (during both visits for longitudinal compari-
son). Venous samples were taken for full blood count, renal 
function, liver function, fasting glucose, lipid profile, thyroid 
function and clotting profile. A full transthoracic echocar-
diogram study was requested if a participant did not have a 
recent echocardiogram. Subsequent measurements were per-
formed in a temperature-controlled room under uniform con-
ditions with participants resting quietly in the supine position 
on a medical examination couch.
2.3 | Measurements
Three serial BP readings were taken over 5 minutes to de-
termine an average. This was followed by assessment of 
participants’ cardiac autonomic function through heart rate 
variability test. Three ECG leads were attached to the chest 
which were then connected to a small portable eMotion Faros 
ECG sensor (eMotion Faros, Bittium Biosignals Ltd). The 
ECG sensor was connected to a laptop with the Cardioscope 
software (Cardioscope Analytics, SMART Medical Ltd) via 
bluetooth to enable real-time ECG rhythm analysis. The ECG 
is analysed in real time for artefacts and arrhythmia to ensure 
accurate results are recorded in the HRV data, automatically 
excluding ectopic beats.
Participants were provided with clear instructions and al-
lowed to practice before readings were taken. Participants 
remained resting quietly on the couch with the ECG sensor 
connected to their chest for a period of 5 minutes and ECG 
data transmitting to the laptop. Following a 5-minute rest pe-
riod, participants were asked to breath in time to a metronome 
device set at 12 breaths per minute while lying on the couch 
for another 5 minutes. The study visit ended and the ECG data 
were subsequently analysed in line with the European Society 
of Cardiology (ESC) and the North America Society of Pacing 
and Electrophysiology standards of measurement of heart rate 
variability.9 The ECG data were independently assessed and 
verified to exclude any artefacts, pauses, ectopics, etc.
The Cardioscope software was unable to provide any 
reliable frequency-domain indices values for permanent 
AF group based on the recommended ESC and the North 
America Society of Pacing and Electrophysiology standards 
of measurement of HRV. This persisted despite re-analys-
ing data with Kubios HRV software (Kubios, Finland).9 
Therefore, frequency-domain analysis was not carried out to 
compare differences between the two groups.
2.4 | Statistical analysis
Descriptive statistics are presented as mean  ±  standard 
deviation (SD) or median with interquartile range, as 
appropriate for continuous variables. Categorical vari-
ables are expressed as numbers and percentages. Statistical 
analysis was performed using SPSS software, version 26 
(SPSS Inc). Continuous variables were tested for normal-
ity using the Shapiro-Wilk test. Non-normally distributed 
data were logarithmically transformed and distribution re-
checked with a Shapiro-Wilk test. If passed, data were ana-
lysed using independent Student's t test (for cross-sectional 
comparison) or Student's paired t test (for longitudinal 
comparison). Data that were still not normally distributed 
were analysed with the Mann-Whitney U test (for cross-
sectional comparison) or Wilcoxon signed rank test (for 
longitudinal comparison). A P value of < .05 was consid-
ered statistically significant.
Associations between HRV indices and co-variates were 
assessed before and after adjustment for potential confound-
ers using linear regression analysis. Multivariable regres-
sion analysis was carried out with individual independent 
variables found to have significant regression on univariable 
analysis adjusted for age, gender, body mass index (BMI), 
presence of ischaemic heart disease (IHD), presence of type 2 
diabetes mellitus (DM) and creatinine clearance (CrCl).
To test specific hypothesis (‘Patients with AF and hyper-
tension will have worse parameters of autonomic function 
compared to hypertension control group’), we recruited 94 
patients in total, split between 2 groups (a) AF and hyper-
tension (b) hypertension control. This part of the study was 
powered based on independent t test, comparing the mean 
rMSSD values across the two groups. Barauskiene et al re-
ported a mean rMSSD value of 29.44 milliseconds (standard 
deviation (SD) = 7.458) in AF group.16 Assuming our SD is 
similar, the minimum sample size was computed as 9 patients 
per group at 90% power, 5% alpha and effect size of 1.69.
3 |  RESULTS
3.1 | Matched AF (and hypertension) group 
vs matched hypertension control group
Participants from the AF (and hypertension) and hyper-
tension control groups were well matched (see Table  1). 
Hypertension control group had more patients with a back-
ground of chronic kidney disease (CKD) (P  =  .01). HRV 
measurements at baseline and with metronome (Table  2) 
show that there were no significant differences in mean 
heart rate between the two groups. Time-domain indices of 
HRV were all significantly higher in the AF (and hyperten-
sion) group compared to the hypertension control group. 
Frequency-domain indices showed no significant differences 
between the two groups.
Nonlinear indices and cardiac vagal index (CVI) were all 
significantly higher in AF (and hypertension) group. Cardiac 
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sympathetic index (CSI) was noted to be significantly lower 
in AF (and hypertension) group. Univariable and multivari-
able analyses of unmatched groups are presented in Table 3. 
AF (P  =  .003), ejection fraction (P  =  .04) and heart rate 
(P = .04) were independently associated with changes seen 
on HRV following adjustment for multiple variables.
T A B L E  1  Demographics and clinical characteristics of AF (and hypertension) group and hypertension control group
Total Matched groups
AF + hypertension
(n = 61)
Hypertension 
control
(n = 33)
AF + hypertension
(n = 40)
Hypertension 
control
(n = 20)
Matched 
groups
P
Demographics
Age, y 71 ± 10 57 ± 12 66 ± 7 65 ± 7 .71
Gender
Male 42 27 29 15 .84
Female 19 6 11 5
Ethnicity
Caucasians, n (%) 53 (86.9%) 13 (39.4%) 34 (85%) 10 (50%) -
Blacks, n (%) 4 (6.6%) 9 (27.3%) 3 (7.5%) 6 (30%)
Asians, n (%) 4 (6.6%) 9 (27.3%) 3 (7.5%) 3 (15%)
Mixed, n (%) 0 (0%) 2 (6%) 0 (0%) 1 (5%)
Clinical characteristics
Heart failure, n (%) 3 (4.9%) 1 (3%) 2 (5%) 0 (0%) .55
IHD, n (%) 10 (16.4%) 7 (21.2%) 5 (12.5%) 5 (25%) .28
Diabetes Mellitus, n (%) 14 (23%) 11 (33.3%) 10 (25%) 8 (40%) .23
Previous stroke/TIA, n (%) 7 (11.5%) 5 (15.2%) 5 (12.5%) 5 (25%) .28
Asthma/COPD, n (%) 13 (21.3%) 3 (9.1%) 5 (12.5%) 2 (10%) .57
Chronic kidney disease, n (%) 1 (1.6%) 5 (15.2%) 1 (2.5%) 5 (25%) .01
Anaemia, n (%) 2 (3.3%) 4 (12.1%) 0 (0%) 2 (10%) .11
Thyroid disorder, n (%) 5 (8.2%) 4 (12.1%) 3 (7.5%) 4 (20%) .21
Hypercholesterolaemia, n (%) 29 (47.5%) 14 (42.4%) 19 (47.5%) 11 (55%) .58
Arthritis, n (%) 30 (49.2%) 10 (30.3%) 24 (60%) 8 (40%) .14
CHA2DS2-VASc score 3 [2-4] 2 [1-3] 2 [2-4] 3 [1-4] .74
HAS-BLED score 1 [1-1] 1 [0-2] 1 [1-1] 2 [1-2] .06
Height (cm) 168.3 ± 9.3 169.9 ± 9.5 170.1 ± 8.9 169.4 ± 11.1 .80
Weight (kg) 88.4 ± 20.3 91.9 ± 13.7 95.5 ± 18.4 92.3 ± 14.7 .50
BMI (kg/m2) 31.0 ± 5.7 31.8 ± 3.7 32.9 ± 5.2 32.1 ± 4.2 .58
Systolic BP (mm/Hg) 145 ± 23 155 ± 25 142 [133-152] 148 [135-175] .12
Diastolic BP (mm/Hg) 79 ± 14 90 ± 16 83 ± 14 85 ± 13 .53
Mean Arterial Pressure (MAP) 
(mm/Hg)
101 ± 14 112 ± 17 103 ± 15 109 ± 16 .23
HbA1c (mmol/mol) 43 ± 9 45 ± 9 41 [39-48] 45 [38-56] .32
CrCl (mL/min) 84.7 ± 32.2 98 ± 30.2 98.8 ± 29.6 85 ± 28.1 .09
Ejection fraction (%) 58 [55-65] 61 [55-66] 58 ± 11 62 ± 7 .14
Note: Descriptive data are presented as numbers (with percentages). Normally distributed data are expressed as mean ± standard deviation. Non-normally distributed 
data are displayed as median with interquartile ranges. Normality test was performed using Shapiro-Wilk test. Statistical differences were tested using an independent t 
test for normally distributed data and Mann-Whitney U test for non-normally distributed data. Categorical data were compared using chi-square test. Where chi-square 
test was not valid, Fisher's exact test was used. Significance P ≤ .05. – = unable to calculate p value as sample size too small/statistical test not valid.
Abbreviations: AF, atrial fibrillation; BMI, Body Mass Index; BP, blood pressure; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; CrCl, 
Creatine Clearance (Cockroft-Gault method); HbA1c, haemoglobin A1C; INR, International Normalised Ratio; TIA, transient ischaemic attack; TSH, thyroid-
stimulating hormone
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T A B L E  2  Differences in heart rata variability (HRV) between AF (and hypertension) and hypertension control groups—cross-sectional 
comparison
Total Matched
AF + hypertension
(n = 61)
Hypertension 
control
(n = 33)
AF + hypertension
(n = 40)
Hypertension 
control
(n = 20)
Matched 
groups
P
Baseline
Mean heart rate (bpm) 63 [60-67]b 62 [58-64]b 63 [60-70]b 61 [56-64]b .09
QTc (ms) 373 [366-380]a 373 [364-382]a 372 [362-382]a 374 [365-383]a .76
Time-domain indices
SDNN (ms) 85 [71-99]a 47 [37-58]a 84 [66-101]a 42 [29-55]a <.001
rMSSD (ms) 103 [41-114]b 27 [20-32]b 106 [30-119]b 25 [20-32]b .01
SDSD (ms) 103 [41-114]b 27 [30-81]b 106 [30-118]b 25 [20-32]b .004
TINN (ms) 440 [360-504]b 304 [200-344]b 444 [344-544]a 272 [205-338]a .02
pNN50 (%) 63 [20-66]b 5 [2-10]b 63 [50-68]b 3 [1-9]b <.001
Frequency-domain indices
VLF (ms2) 749 [279-1470]b* 1285 [814-1677]b 972 [498-1447]a* 1577 [848-2306]a .16
LF (ms2) 361 [169-627]b* 567 [247-1048]b 252 [143-444]a* 384 [225-654]a .26
HF (ms2) 239 [92-621]b* 314 [215-527]b 180 [102-317]a* 241 [154-377]a .39
Total Power (ms2) 1468 [713-2601]b* 2552 [1314-3052]b 1739 [887-2592]a* 2204 [1617-2791]a .34
LF normalised (%) 49 [42-59]b* 62 [56-69]b 56 [47-64]a* 61 [54-67]a .34
HF normalised (%) 51 [41-58]b* 38 [31-44]b 44 [36-53]a* 39 [33-46]a .34
LF-i/HF-i 0.9 [0.7-1.1]b* 1.6 [1.3-2.1]b 1.2 [0.8-1.7]a* 1.5 [1.1-2.0]a .26
Nonlinear indices
SD1 (ms) 73 [29-80]b 19 [14-23]b 75 [21-84]b 18 [14-22]b .004
SD2 (ms) 98 [82-114]a 63 [48-77]a 97 [76-118]a 55 [38-71]a .002
SD1/SD2 0.6 [0.5-0.7]b 0.4 [0.3-0.5]b 0.6 [0.5-0.7]a 0.4 [0.3-0.5]a .001
CVI 3.5 [3.4-3.7]a 3.0 [2.8-3.2]a 3.5 [3.3-3.8]a 2.9 [2.7-3.2]a .003
CSI 1.8 [1.6-2.0]a 2.8 [2.5-3.1]a 1.8 [1.5-2.1]a 2.6 [2.2-3.0]a .003
With metronome
Mean heart rate (bpm) 67 [63-72]b 62 [58-68]b 66 [61-72]a 60 [56-66]a .12
QTc (ms) 372 [363-381]b 378 [360-384]b 371 [361-382]a 375 [366-384]a .64
Time-domain indices
SDNN (ms) 76 [47-89]b 39 [28-51]b 62 [48-80]a 33 [27-41]a <.001
rMSSD (ms) 86 [35-101]b 29 [21-37]b 97 [35-105]b 26 [20-37]b .002
SDSD (ms) 90 [41-101]b 29 [21-37]b 91 [54-104]b 26 [20-37]b <.001
TINN (ms) 392 [328-456]b 256 [184-320]b 332 [258-428]a 230 [181-293]a .047
pNN50 (%) 58 [25-62]b 7 [2-20]b 58 [25-64]b 5 [1-17]b <.001
Frequency-domain indices
VLF (ms2) 478 [262-986]b* 578 [314-1099]b 462 [199-1158]b* 513 [178-785]b .72
LF (ms2) 265 [133-818]b* 360 [177-690]b 289 [127-659]a* 253 [141-454]a .78
HF (ms2) 385 [165-630]b* 299 [198-536]b 339 [169-681]a* 267 [176-406]a .53
Total Power (ms2) 914 [610-2061]b* 1507 [800-2414]b 795 [421-1502]a* 1103 [726-1675]a .35
LF normalised (%) 40 [34-47]a* 50 [43-57]a 42 [33-52]a* 48 [38-58]a .39
HF normalised (%) 60 [53-66]a* 50 [43-57]a 58 [48-67]a* 52 [42-62]a .39
LF-i/HF-i 0.6 [0.4-0.8]b* 0.9 [0.6-1.3]b 0.7 [0.5-1.1]a* 0.8 [0.6-1.2]a .61
(Continues)
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3.2 | Permanent AF (and hypertension) 
group vs PAF (and hypertension) group
Participants in the permanent AF and PAF groups were also 
well matched (Table 4). Participants in PAF group had signif-
icantly greater prevalence of ischaemic heart disease (IHD) 
(P  =  .01). There were no significant differences in mean 
heart rate, or mean corrected QT interval between the two 
groups (Table  5). All time-domain HRV indices were sig-
nificantly higher in permanent AF group compared to parox-
ysmal AF group at baseline and with metronome. Similarly, 
all nonlinear indices were found to be significantly higher in 
permanent AF group compared to paroxysmal AF group ex-
cept for CSI which was significantly lower in the permanent 
AF group. Permanent AF was the only independent predictor 
of HRV on multivariable analysis in this cohort of patients 
(P = .006) (Table 3).
3.3 | Permanent AF (and hypertension) 
group—longitudinal comparison
Following optimisation of BP and heart rate medication, 
patients with permanent AF (and hypertension) were fol-
lowed up after 8  weeks and HRV repeated. There were 
significant reductions in mean heart rate (77 beats per 
minute (bpm) ± 18 (baseline) vs 72  bpm  ±  17 (follow-
up), P  =  .01), systolic BP (141  mmHg  ±  20 (baseline) 
vs 134  mmHg  ±  17 (follow-up), P  =  .01), diastolic 
BP (81  mmHg  ±  13 (baseline) vs 77  mmHg  ±  12 (fol-
low-up), P  =  .009) and mean arterial pressure (MAP) 
(101 mmHg ± 12 (baseline) vs 96 mmHg ± 10 (follow-
up), P =  .005). HRV measurements at baseline and with 
metronome showed no significant differences in time-do-
main and nonlinear indices (Table 6).
4 |  DISCUSSION
Our findings show for the first time that HRV is higher in pa-
tients with AF (and hypertension) compared to hypertension 
alone. Second, we observed that HRV is higher in permanent 
AF compared to paroxysmal AF. Finally, optimisation of AF 
or BP control medications was found not to improve HRV. 
HRV has been studied extensively in patients with normal 
sinus rhythm and shown to have important prognostic im-
plications for various cardiovascular disorders.9-12 However, 
there have been relatively few published reports dealing with 
the phenomenon in AF and none looking at AF and hyperten-
sion together.13-15 Even when studies have looked at AF, they 
have typically measured HRV when patients were in sinus 
rhythm.13-15
van den Berg et al, however, did assess HRV in patients 
in AF.13 They hypothesised that patterning of ventricular 
rhythm is possible in patients with AF given the function of 
the atrioventricular (AV) node in AF and its susceptibility 
to cardiac autonomic influences.13 Compared to controls, 
HRV was higher in patients with AF, while intravenous 
administration of the beta-adrenergic antagonist proprano-
lol (0.2  mg/kg) increased HRV in both groups. HRV was 
subsequently reduced by intravenous administration of the 
muscarinic antagonist methylatropine (0.02 mg/kg), and the 
Total Matched
AF + hypertension
(n = 61)
Hypertension 
control
(n = 33)
AF + hypertension
(n = 40)
Hypertension 
control
(n = 20)
Matched 
groups
P
Nonlinear indices
SD1 (ms) 64 [29-71]b 20 [15-26]b 65 [38-74]b 18 [14-26]b <.001
SD2 (ms) 83 [58-104]b 45 [34-68]b 90 [72-108]a 47 [36-58]a <.001
SD1/SD2 0.7 [0.5-0.7]b 0.4 [0.4-0.5]b 0.7 [0.6-0.7]a 0.5 [0.4-0.5]a .002
CVI 3.5 [3.3-3.7]a 3.0 [2.9-3.2]a 3.5 [3.3-3.7]a 2.9 [2.7-3.1]a <.001
CSI 1.7 [1.5-1.9]a 2.4 [2.2-2.6]a 1.7 [1.4-1.9]a 2.2 [1.9-2.4]a .003
Note: Bold values indicates significant P values.
Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified by superscript a. Non-normally distributed data are displayed as median 
[95% CI]. Identified by superscript b. Normality test was performed using Shapiro-Wilk test. Statistical differences were tested using independent t test (for parametric 
data) or Mann-Whitney U test (for nonparametric data). Significance P ≤ .05. * = data presented only for paroxysmal AF patients.
Abbreviations: AF, atrial fibrillation; CSI, cardiac sympathetic index; CVI, cardiac vagal index; HF, high frequency (0.15 - 0.4 Hz); LF, low frequency (0.04 - 
0.15 Hz); pNN50, NN50 count divided by the total number of all NN intervals; QTc, corrected QT interval, SDNN, standard deviation of all NN intervals; rMSSD, 
square root of the mean of the sum of the squares of differences between adjacent NN intervals; SD1, standard deviation of the distance of each point from the y, x 
axis, specifies the ellipse's width; SD2, standard deviation of each point from the y, x + average R-R interval, specifies the ellipse's length; SDSD, standard deviation 
of differences between adjacent NN intervals; TINN, triangular interpolation of the NN interval histogram; VLF, very low frequency (≤0.04 Hz).
T A B L E  2  (Continued)
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magnitude of this reduction in HRV significantly correlated 
with the decrease in mean RR interval (used by the authors 
as an index of ‘cardiac vagal control’). In light of these find-
ings, it was concluded that HRV during AF is related to 
vagal tone.
Our study has shown for the first time that all time-do-
main metrics of HRV were significantly higher in AF (and 
hypertension) group compared to hypertension control 
group. Time-domain indices of HRV quantify the amount of 
variability in measurements of the interbeat interval (IBI), 
Variable
Univariable Multivariablea 
R2 F P R2 F P
AF (and hypertension) vs hypertension control
Dependent variable: Baseline rMSSD
AF 0.206 23.160 <.001 0.222 3.387 .003
Age 0.083 8.016 .006 0.123 1.971 .08
EF 0.056 5.065 .03 0.170 2.309 .03
Ethnicity 0.054 5.068 .03 0.129 1.760 .11
CKD 0.044 4.054 .05 0.144 1.991 .07
Dependent variable: Baseline SD1
AF 0.210 23.904 <.001 0.224 3.456 .003
Age 0.073 7.131 .009 0.115 1.836 .10
EF 0.058 5.326 .02 0.163 2.226 .04
Ethnicity 0.055 5.283 .02 0.123 1.688 .12
CKD 0.044 4.150 .05 0.135 1.878 .08
Dependent variable: Metronome pNN50
AF 0.236 26.546 <.001 0.260 4.020 .001
CKD 0.059 5.367 .02 0.151 2.034 .06
Heart rate 0.054 4.876 .03 0.162 2.210 .04
Ethnicity 0.053 4.825 .03 0.118 1.526 .17
Age 0.051 4.663 .03 0.110 1.673 .14
Dependent variable: Metronome SD1
AF 0.199 21.800 <.001 0.219 3.283 .004
Age 0.065 6.152 .02 0.108 1.677 .14
Permanent AF (and hypertension) vs paroxysmal AF (and hypertension)
Dependent variable: Baseline pNN50
AF 0.535 61.067 <.001 0.546 8.088 <.001
IHD 0.109 6.510 .01 0.128 1.170 .34
Diastolic BP 0.102 6.045 .02 0.225 1.952 .08
EF 0.099 5.616 .02 0.210 1.706 .13
Dependent variable: Baseline SD2
AF 0.232 17.208 <.001 0.310 3.281 .006
IHD 0.072 4.414 .04 0.123 1.210 .32
Dependent variable: Metronome rMSSD
AF 0.096 5.392 .02 0.201 1.620 .15
Dependent variable: Metronome SD2
AF 0.235 16.916 <.001 0.358 3.906 .002
Note: Bold values indicates significant P values.
Abbreviations: AF, atrial fibrillation; CKD, chronic kidney disease; EF, ejection fraction; IHD, ischaemic heart 
disease
aAdjusted for age, sex, BMI, presence of ischaemic heart disease (IHD), presence of type 2 diabetes mellitus 
(DM) and creatinine clearance (CrCl). 
T A B L E  3  Univariable and 
multivariable regression analyses
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which is the time period between successive heartbeats.19 Put 
simply, participants in our AF (and hypertension) group were 
found to have higher HRV, beyond that seen in non-AF hy-
pertensives. Indeed, AF is characterised by marked HRV.13,17 
Compared to previous studies, our study included more pa-
tients, did not require administration of intravenous rate 
limiting medication such as propranolol, which could be an 
important confounder and was performed prospectively with 
study data recorded in real time as oppose to retrospective 
analysis of 24-hour ambulatory electrocardiographic re-
cordings.13,17 Furthermore, we controlled our participants’ 
breathing rate using a metronome to reduce its confounding 
T A B L E  4  Demographics and clinical characteristics of permanent AF (and hypertension) group and paroxysmal AF (and hypertension) group
Permanent AF + hypertension
(n = 30)
Paroxysmal AF + hypertension
(n = 31) P
Demographics
Age, years 70 ± 8 72 ± 11 .64
Gender
Males 22 20 .46
Females 8 11
Ethnicity
Caucasians, n (%) 28 (93.3%) 25 (80.6%) -
Blacks, n (%) 1 (3.3%) 3 (9.7%)
Asians, n (%) 1 (3.3%) 3 (9.7%)
Mixed, n (%) 0 (0%) 0 (0%)
Clinical characteristics
Heart failure, n (%) 3 (10%) 0 (0%) .11
IHD, n (%) 0 (0%) 10 (32.3%) <.001
Diabetes Mellitus, n (%) 7 (23.3%) 7 (22.6%) .81
Previous stroke/TIA, n (%) 5 (16.7%) 2 (6.5%) .26
Asthma/COPD, n (%) 9 (30%) 4 (12.9%) .10
Chronic kidney disease, n (%) 0 (0%) 1 (3.2%) 1.00
Anaemia, n (%) 1 (3.3%) 1 (3.2%) 1.00
Thyroid disorder, n (%) 1 (3.3%) 4 (12.9%) .35
Hypercholesterolaemia, n (%) 14 (46.7%) 15 (48.4%) .89
Arthritis, n (%) 14 (46.7%) 16 (51.6%) .70
CHA2DS2-VASc score 3 [2-4] 3 [2-4] .56
HAS-BLED score 1 [1-1] 1 [1-1] .18
Height (cm) 169.3 ±± 8.4 167.3 ± 10.1 .40
Weight (kg) 89.6 ± 19.1 87.2 ± 21.7 .66
BMI (kg/m2) 31.1 ± 5.1 31.0 ± 6.3 .95
Systolic BP (mm/Hg) 140 [128-148] 144 [134-153] .24
Diastolic BP (mm/Hg) 81 ± 13 76 ± 15 .16
Mean Arterial Pressure (MAP) (mm/Hg) 101 ± 12 101 ± 16 .87
HbA1c (mmol/mol) 41 [38-46] 41 [40-51] .94
CrCl (mL/min) 86.2 ± 30.8 75.9 ± 38.1 .72
Ejection fraction (%) 55 [55-62] 62 [55-68] .22
Note: Bold values indicates significant P values.
Descriptive data are presented as numbers (with percentages). Normally distributed data are expressed as mean ± standard deviation. Non-normally distributed data 
are displayed as median with interquartile ranges. Normality test was performed using Shapiro-Wilk test. Statistical differences were tested using an independent t test 
for normally distributed data and Mann-Whitney U test for non-normally distributed data. Categorical data were compared using chi-square test. Where chi-square test 
was not valid, Fisher's exact test was used. Significance P ≤ .05. – = unable to calculate p value as sample size too small/statistical test not valid.
Abbreviations: AF, atrial fibrillation; BMI, Body Mass Index; BP, blood pressure; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; CrCl, 
Creatine Clearance (Cockroft-Gault method); HbA1c, haemoglobin A1C; INR, International Normalised Ratio; TIA, transient ischaemic attack; TSH, thyroid-
stimulating hormone.
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influence. It is well established that variation in respiratory 
rate affects HRV analysis.20-22
SDNN (standard deviation of all NN intervals) which 
reflect the sum contribution of both the sympathetic ner-
vous system (SNS) and parasympathetic nervous system 
(PNS) was found to be significantly higher in the AF group 
compared to hypertension control group in our study which 
suggests that perhaps both limbs of cardiac ANS are in-
vested in the pathophysiology of development and prop-
agation of AF. Certainly, this supports data observed in 
previous studies.6,7 The rMSSD (square root of the mean 
of the sum of the squares of differences between adjacent 
NN intervals) and pNN50% (the percentage of adjacent 
RR intervals that differed by more than 50 ms) are more 
T A B L E  5  Differences in heart rata variability (HRV) between permanent AF and paroxysmal AF groups—cross-sectional comparison
Permanent AF + hypertension group
(n = 30)
Paroxysmal AF + hypertension group
(n = 31) P
Baseline
Mean heart rate (bpm) 71 [65-76]a 65 [58-72]a .19
QTc (ms) 372 [361-384]a 374 [364-383]a .86
Time-domain indices
SDNN (ms) 111 [101-122]a 61 [39-83]a <.001
rMSSD (ms) 115 [107-132]b 28 [21-41]b <.001
SDSD (ms) 115 [106-130]b 28 [21-41]b <.001
TINN (ms) 574 [496-653]a 379 [268-489]a .006
pNN50 (%) 68 [63-70]b 7 [2-20]b <.001
Nonlinear indices
SD1 (ms) 82 [75-92]b 20 [15-29]b <.001
SD2 (ms) 129 [114-143]a 70 [47-94]a <.001
SD1/SD2 0.7 [0.6-0.8]a 0.5 [0.4-0.6]a .006
CVI 4.0 [4.0-4.1]a 3.1 [2.8-3.4]a <.001
CSI 1.5 [1.3-1.6]a 2.1 [1.8-2.5]a .001
With metronome
Sinus rhythm (%) 14 [4-24]b 99 [98-100]b <.001
Mean heart rate (bpm) 75 [68-82]a 66 [60-71]a .03
QTc (ms) 371 [360-383]a 375 [365-386]a .60
Time-domain indices
SDNN (ms) 90 [82-113]b 39 [28-59]b <.001
rMSSD (ms) 103 [97-118]b 33 [23-54]b .002
SDSD (ms) 101 [97-114]b 33 [23-54]b <.001
TINN (ms) 496 [432-560]a 365 [281-449]a .03
pNN50 (%) 64 [61-70]b 11 [4-28]b <.001
Nonlinear indices
SD1 (ms) 72 [69-80]b 23 [17-38]b <.001
SD2 (ms) 104 [96-137]b 51 [35-65]b <.001
SD1/SD2 0.7 [0.6-0.8]a 0.6 [0.5-0.7]a .15
CVI 3.9 [3.8-4.0]b 3.0 [2.8-3.3]b <.001
CSI 1.5 [1.3-1.6]a 1.7 [1.4-2.0]a .15
Note: Bold values indicates significant P values.
Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified by superscript a. Non-normally distributed data are displayed as median 
[95% CI]. Identified by superscript b. Normality test was performed using Shapiro-Wilk test. Statistical differences were tested using independent t test (for parametric 
data) or Mann-Whitney U test (for nonparametric data). Significance P ≤ .05. – = unable to calculate p value as sample size too small/statistical test not valid.
Abbreviations: AF, atrial fibrillation; CSI, cardiac sympathetic index; CVI, cardiac vagal index; pNN50, NN50 count divided by the total number of all NN intervals; 
QTc, corrected QT interval, SDNN, standard deviation of all NN intervals; rMSSD, square root of the mean of the sum of the squares of differences between adjacent 
NN intervals; SDSD, standard deviation of differences between adjacent NN intervals; TINN, triangular interpolation of the NN interval histogram.
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influenced by the PNS than SDNN. In our study, we found 
that rMSSD and pNN50% were significantly higher in AF 
(and hypertension) group. This suggests a high vagal tone 
in these patients.
Frequency-domain measurements employ autoregres-
sive modelling to separate HRV into its components, such 
as ultra-low frequency (ULF), very low frequency (VLF), 
low frequency (LF) and high frequency (HF) rhythms that 
operate within different frequency ranges.8 We hypothesise 
that the erratic ventricular response to random atrial im-
pulses seen in permanent AF would have led to generation of 
‘noise’ which would have prevented the HRV software from 
Permanent 
AF + hypertension
(Baseline)
Permanent 
AF + hypertension
(Follow-up) P
Baseline
Mean heart rate 
(bpm)
71 [65-76]a 69 [63-76]a .74
QTc (ms) 369 [355-381]b 377 [362-384]b .92
Time-domain indices
SDNN (ms) 100 [95-122]b 105 [82-129]b .67
rMSSD (ms) 123 [114-134]a 115 [101-132]a .23
SDSD 123 [114-133]a 121 [106-137]a .56
TINN (ms) 504 [472-584]b 508 [432-528]b .96
pNN50% 68 [63-70]b 71 [62-86]b .18
Nonlinear indices
SD1 (ms) 87 [80-94]a 85 [75-97]a .56
SD2 (ms) 120 [106-151]b 121 [95-144]b .84
SD1/SD2 0.7 [0.6-0.8]b 0.7 [0.6-0.8]b 1.00
CVI 4.0 [3.9-4.1]b 4.0 [3.8-4.1]b .09
CSI 1.5 [1.3-1.6]a 1.4 [1.3-1.6]a .85
With metronome
Mean heart rate 
(bpm)
75 [68-82]a 72 [65-79]a .39
QTc (ms) 372 [360-384]a 371 [362-379]a .56
Time-domain indices
SDNN (ms) 97 [86-109]a 101 [82-125]a .92
rMSSD (ms) 104 [98-118]b 111 [92-133]b .47
SDSD 108 [98-120]a 108 [96-122]a .97
TINN (ms) 496 [432-560]a 500 [431-570]a .23
pNN50% 64 [61-70]b 66 [59-71]b .87
Nonlinear indices
SD1 (ms) 77 [69-85]a 76 [68-86]a .97
SD2 (ms) 104 [96-137]b 116 [89-158]b .78
SD1/SD2 0.7 [0.6-0.7]b 0.6 [0.6-0.9]b .76
CVI 3.9 [3.8-4.0]b 3.9 [3.8-4.1]b .88
CSI 1.5 [1.3-1.7]b 1.6 [1.2-1.8]b .90
Note: Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified by 
superscript a. Non-normally distributed data are displayed as median [95% CI]. Identified by superscript b. 
Normality test was performed using Shapiro-Wilk test. Statistical differences were tested using paired t test (if 
passed) or Wilcoxon signed rank test (if failed). Significance P ≤ .05.
Abbreviations: AF, atrial fibrillation; CSI, cardiac sympathetic index; CVI, cardiac vagal index; pNN50, NN50 
count divided by the total number of all NN intervals; QTc, corrected QT interval; rMSSD, square root of the 
mean of the sum of the squares of differences between adjacent NN intervals; SDNN, standard deviation of 
all NN intervals; SDSD, standard deviation of differences between adjacent NN intervals; TINN, triangular 
interpolation of the NN interval histogram.
T A B L E  6  Differences in heart rata 
variability (HRV) in permanent AF group—
longitudinal comparison
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interpreting the data consistently, a notion supported by Frey 
et al15 Another possible explanation could be that the peak 
variability in these patients was perhaps occurring beyond 
the high-frequency range in AF, and therefore, our HRV soft-
ware was unable to capture this.
Possible reasons for not seeing any significant differences 
in frequency-domain indices between the AF (and hyperten-
sion) and hypertensive control groups could be that patients 
had similar demographic profiles (age, gender and ethnic-
ity), similar clinical characteristics and baseline heart rate. 
It is well established that age, gender, clinical characteristics, 
heart rate and blood pressure can all affect HRV.23-27 Another 
reason could be the shorter length of HRV recording (5 min-
utes as oppose to the gold standard 24  hours), which may 
have masked any differences.28
Similar to time-domain metrics, nonlinear indices of 
HRV were found to be significantly higher in AF (and hy-
pertension) group compared to hypertension control group. 
One of the key markers in the nonlinear metrics is the car-
diac vagal index (CVI), which represents the contribution 
of the PNS to cardiac regulation and is found to be a more 
reliable metric.29,30 CVI sets the parameters SD1 and SD2 
into a direct relationship and therefore serves to capture the 
parasympathetic (vagal) activity. In our study, it was found 
to be significantly higher in patients with AF. Conversely, 
the cardiac sympathetic index (CSI) representing the con-
tribution of SNS to cardiac regulation was noted to be 
significantly lower in the AF group.30,31 Higher CSI is as-
sociated with lower variability.31 This further supports our 
previous findings.
It is well known that vagal stimulation contributes to the 
development of AF by heterogenous shortening of action 
potential duration and refractory period through actions of 
acetylcholine (ACh) on the muscarinic receptors found in 
the heart.2 Additionally, recent studies have shown evidence 
of noncholinergic vagal effects that may also contribute to 
the pathogenesis of vagally induced AF.32,33 Lastly, there is 
a pronounced vagal innervation of the atrial muscle sleeves 
extending into the pulmonary veins, a site well known for 
AF origin.34 All of this combined can help explain the HRV 
findings in our study.
It is well known that HRV is strongly influenced by re-
spiratory rate.19,20,22 Respiratory rate changes can produce 
large-scale shifts in respiratory sinus arrhythmia magnitude 
without affecting vagal tone.35 Therefore, we attempted 
to control the respiratory rate by asking our participants to 
control their breathing with help of a metronome to reduce 
this bias and repeated HRV measurements over 5 minutes. 
Overall, there were no significant differences in the data ob-
tained with and without metronome and the conclusions from 
the data were similar, which was reassuring.
The second part of the study compared permanent 
AF with paroxysmal AF and found significantly higher 
time-domain and nonlinear indices of HRV in permanent AF, 
which may suggest pronounced cardiac autonomic influence 
in the pathophysiology of permanent AF. Similar to first part 
of the study, using a metronome did not change the data sig-
nificantly when compared with baseline data except for SD1/
SD2 ratio and CSI, which now showed no significant differ-
ences between the two AF groups. SD1/SD2 ratio and CSI 
are both markers of sympathetic activity. It is previously un-
derstood that controlled breathing can influence sympathetic 
activity, as seen in our study.19 For the last part of our study, 
although there are interventions that modulate cardiac auto-
nomic activity and thus reduce the incidence of spontaneous 
or induced atrial arrhythmias, this was not observed in our 
study.36-40
4.1 | Strengths and limitations
As far as we are aware, this is the first study to look at 
HRV in patients with AF and hypertension. Participants 
in our groups were well matched for age, gender and co-
morbidities. Our study does have several limitations, such 
as modest sample sizes, raising the potential for a type II 
error, which may contribute to the small number of inde-
pendent associations in our univariable and multivariable 
analyses. The cross-sectional design is another limitation 
of our study. We also acknowledge the redundancy be-
tween rMSSD and SD1.19 The erratic nature of permanent 
AF rhythm prevented the HRV software to produce any 
frequency-domain information. The follow-up period of 
8 weeks in the longitudinal study may not be enough to ob-
serve any changes in HRV and may explain no differences 
observed in HRV.
It is perceived that antihypertensives and other med-
ications affect cardiac autonomic function. The use of 
cardiovascular medications including rate control, antihy-
pertensives and anticoagulants at baseline in our partici-
pants was according to clinical indication, and therefore, 
we cannot exclude their possible influence on HRV. 
Furthermore, it is possible that patients in one group were 
more adherent to cardiovascular medications, and this may 
have affected our results. Lastly, ANS function is known 
to be confounded by a large number of lifestyle-related 
and cardiometabolic factors, including sleep, sitting time, 
physical activity, fitness parameters and socioeconomics. 
While we have included in our regression analysis some of 
these factors, such as smoking, alcohol intake, biomarkers 
(HbA1c, creatinine clearance), we cannot completely ex-
clude the possibility of other lifestyle factors that may have 
affected our results.
In summary, we have shown that AF independent of 
hypertension is characterised with marked HRV and is 
predominantly related to vagal tone. Second, HRV is more 
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pronounced in permanent AF as oppose to paroxysmal AF, 
with AF being an independent predictor of HRV on uni-
variable and multivariable analyses. Further studies should 
attempt to look at the role of HRV in the pathogenesis of 
permanent AF, how HRV can be modulated through vari-
ous interventions and assess its long-term implications. In 
patients with difficult to manage AF, autonomic influences 
should be considered as a contributory factor and inves-
tigated further to see whether neuromodulation through 
drugs may be helpful.
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